

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and Cour Pharmaceutical Development Company, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the UMOR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Committee and agreed to by the parties involved.

This proposed research agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professor Lonnie Shea is an employee of the University of Michigan ("University"), and a partial owner of Cour Pharmaceutical Development Company, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. Lonnie Shea, a Professor and Chair in the Department of Biomedical Engineering, is a partial owner of a for-profit company called Cour Pharmaceutical Development Company, Inc. (the "Company"). The Company wishes to fund a project entitled "Tolerizing particles for pemphigus vulgaris" (ORSP# 15-PAF08045) in the Department of Biomedical Engineering under the direction of Dr. Lonnie Shea. The purpose of this project is to manufacture TIMP-DSG3 and OVA control particles.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately three (3) months. The amount of funding support will not exceed \$10,000. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement

The Agreement will support an effort by Dr. Shea to use his expertise and University laboratory, as well as other University resources, to manufacture TIMP-DSG3 and OVA control particles.

Recommendations:

This matter has been reviewed and approved by the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with Cour Pharmaceutical Development Company, Inc.

Respectfully submitted,



S. Jack Hu
Interim Vice President for Research

November 2015